Prevalence of metabolic dysfunction-associated fatty liver disease after pancreatic surgery in a historical Belgian cohort and review of the literature
Journal | Volume 87 - 2024 |
Issue | Fasc.3 - Original articles |
Author(s) | V. D’Cruz 1 #, A. De Zutter 1 2 #, M. Van den Broecke 3 4, S. Ribeiro 1, L. Abreu de Carvalho 5, P. Smeets 3, C. Lecluyse 3, E. Pape 5, E. Callebout 1, F. Berrevoet 5, K. Geboes 1 6 |
Full article |
PAGES 373-380 VIEW FREE PDF |
DOI | 10.51821/87.3.10078 |
Affiliations: (1) Ghent University Hospital, department of Gastroenterology, Ghent, Belgium
(2) Sint-Andriesziekenhuis, department of Gastroenterology, Tielt, Belgium (3) Ghent University Hospital, department of Radiology, Ghent, Belgium (4) Sint Vincentiusziekenhuis, department of Radiology, Deinze, Belgium (5) Ghent University Hospital, General and HPB Surgery and Liver Transplantation, Ghent, Belgium (6) Ghent University Hospital, Cancer Centre, Ghent, Belgium (#) Contributed equally |
Background and objectives: Metabolic dysfunction-associated fatty liver disease (MAFLD) has been reported as a complication after pancreatic surgery. The aim of this study is to assess this phenomenon in a Belgian population, specifically in a period in time when less perioperative chemotherapy was given. Methods: We performed a retrospective monocentric cohort study with 124 selected patients who underwent pancreatic surgery – pancreaticoduodenectomy (PD), distal pancreatectomy (DP) or total pancreatectomy – between 2005 and 2014. Steatosis was assessed radiologically, using Hounsfield units on liver and spleen. Data on imaging, liver function, weight and other relevant parameters were gathered preoperatively as well as 2 and 6 months, 1 and 2 years after surgery. Results: Thirty-eight (31%) out of 124 patients developed liver steatosis at least at one point in time in the two years following surgery, with a prevalence of 21.0% at 2 months, 28.6% at 6 months, 16.4% at 1 year and 20.8 % at 2 years. A statistically significant association with preoperative AST and ALT values, administration of pancreatic enzyme supplementation as a surrogate for pancreatic exocrine insufficiency (PEI) and weight loss at 2 years was detected. Conclusion: MAFLD is seen in 31% of patients with PD or DP pancreatic resection in this retrospective analysis of a monocentric Belgian cohort. Both early and late onset of MAFLD was observed, implying that long-term follow-up is necessary. Clinical impact as well as a direct correlation with patients’ weight and oral enzyme supplements needs to be further investigated. Keywords: metabolic dysfunction-associated fatty liver disease, pancreatic surgery, pancreatic exocrine insufficiency. |
© Acta Gastro-Enterologica Belgica. PMID 39411790 |